|Articles|December 2, 2022

Merck, BigHat BioSciences Collaborate on Drug Discovery Programs

Biotech company’s AI/machine learning-enabled platform to design candidates for up to three drug discovery programs

Merck, known as MSD outside of the US and Canada, and BigHat BioSciences, a biotechnology company specializing in machine learning (ML)-guided antibody discovery and development, have established a research collaboration in which Merck will use BigHat’s Milliner platform to design candidates for up to three drug discovery programs.

The Milliner platform combines high-speed characterization with ML capabilities to engineer antibodies with more complex functions and better biophysical properties. The goal of this approach is to reduce the difficulty of optimizing antibodies and other therapeutics.

“We are excited to begin this collaboration to advance next-generation antibody therapeutics to patients,” says Elizabeth Schwarzbach, BigHeat’s chief business officer. "This agreement with Merck brings us a major step closer to our goal of three to five deep collaborations with leading biopharmas to complement our internal therapeutic pipeline."

Read more about the partnership here.


Related to this article

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS). | © Tada Images - stock.adobe.com 521699065
In this week’s Pharma Pulse, the FDA launches a program that lets companies share its approval packages with foreign regulators, UPS agrees to acquire Australia and New Zealand health care courier Smartways Logistics and Cognizant introduces an AI-enabled patient hub offering.